About US
Contact us
-
Patheon's Banner buyout adds to lossesPatheon's $255 million buyout last year of Mexico's Banner Pharmacaps gave the contract manufacturer a beachhead in the fast-growing Latin American market. But it lost something along the way. The No2013/3/11
-
UPDATED: Bayer, J&J test Xarelto uses, even as ACS indication eludesJohnson & Johnson ($JNJ) and Bayer AG are looking on the bright side of things when it comes to Xarelto. They are undertaking new trials they hope will lead to much wider use of the new kind of b2013/3/11
-
Activartis Receives Orphan Drug Designation for its Cancer Immune Therapy AV0113The European Medicines Agency recently awarded the Austrian biotech company ctivartis an Orphan Drug Designation for its innovative Cancer Immune Therapy AV0113. The Orphan Drug Designation applies s2013/3/8
-
New Drug Discovery Company CoCo Therapeutics Ltd Created to Progress Retinoic Acid Receptor Alpha Agonist for Alzheimer’s DiseasKing’s College London, The Wellcome Trust and Advent Venture Partners today announced theformation of a new UK biotechnology company, CoCo Therapeutics Ltd, to progress the research of Professor Jonat2013/3/8
-
Sixth Merck Serono Spin-off Company to Focus on Gastrointestinal Immunological DisordersNewly formed Calypso Biotech will continue research and development of preclinical antibody programs from Merck Serono Merck Serono, a division of Merck, Darmstadt, Germany, announced today thecre2013/3/7
-
FDA panel looks askance at calcitonin bone drugsNew restrictions may be in store for a long-used set of bone-building drugs. Worried about a possible increase in cancer risk--and unconvinced of the drugs' benefits--an FDA advisory panel voted agai2013/3/7
-
Pfizer nabs extra time with blockbuster Celebrex patentThank you, U.S. patent office. Pfizer ($PFE) won an extra 18 months of exclusivity for its pain drug Celebrex, in the form of a reissued patent that doesn't expire till the end of 2015. That means a2013/3/6
-
GSK, Hospira litigation highlights danger in contract manufacturingContract manufacturing can solve all kinds of problems and save all kinds of money, but if things go bad it can bring on a world of hurt. When Boehringer Ingelheim's Ben Venue plant had to close down2013/3/6
-
Novartis pay furor swayed vote on Swiss restrictions, official saysThe Swiss have spoken on executive pay. In a national referendum, two-thirds of voters approved sweeping new restrictions. It was a thump on the head to companies that bestow increasingly lavish comp2013/3/5
-
India sinks Bayer's hopes on Nexavar patentIt is a not-so-happy anniversary for Germany's Bayer AG. A year after the company became the first to have a drug targeted by India's compulsory licensing law, an appeals board has said there will be2013/3/5